The purpose of this project is to implement and evaluate the effectiveness of the 4 Pillars Practice Transformation Program to increase uptake of the HPV vaccine among pediatric patients.
Extending the current human papillomavirus (HPV) vaccination program to age 45 years is expected to produce small additional reductions in HPV-associated diseases with high additional costs.
Mailing human papillomavirus (HPV) kits to underscreened women is associated with increased screening uptake but does not significantly increase precancer detection or treatment.
In 2012 to 2016, an estimated 92% of cancers attributable to HPV were due to HPV types targeted by the 9vHPV vaccine.
Educational interventions delivered in a clinical setting may improve vaccination behaviors.
Parents of racial or ethnic minority adolescents were more likely to inaccurately report HPV vaccination initiation.
Following diagnosis, 66.2% of women with the disease survive 5 or more years.1 HPV causes the majority of cervical cancer cases.
The US Preventive Services Task Force recommends cervical cancer screening with cervical cytology alone every 3 years or screening with high-risk human papillomavirus testing alone every 5 years.
While more teenagers are now starting the HPV vaccination dose cycle, many still aren’t completing the full series.
Men have higher standardized incidence ratio than women for second primary malignancy.
